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ABSTRACT 
Efficacy of pharmaceuticals dosage form generally depends on their formulation properties and manufacturing methods, hence it is likely that 
the quality of dosage form may vary. Renin acts on angiotensinogen to form angiotensin I, which is converted to angiotensin II by angiotensin-
converting enzyme (ACE). Angiotensin II, a potent vasoconstrictor increases blood pressure by increasing vasopressin production and 
aldosterone secretion. Enalaprilat, the active metabolite of enalapril, inhibits ACE, hence decreases levels of angiotensin II resulting in less 
vasoconstriction and decreased blood pressure. The study was exclusively experimental that used IP and other standard books to check in vitro 
quality of enalapril maleate tablet using different analytical techniques and procedure. Test for weight variation, hardness, friability, 
disintegration time, and dissolution were conducted. The dissolution test was performed at pH 6.8 for both the brands of the tablet. Further all 
the tablets passed weight variation, hardness, friability and disintegration test as per the pharmacopoeial standard. Hence we can conclude that 
both the brands of tablets are equal and both the brands contain equal quantity of active pharmaceutical ingredient (API). Both the brands 
having higher and lower costs exert similar action. 
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INTRODUCTION 
Post marketing surveillance works as a confidential tool to 
analyze the quality, therapeutic effectiveness and safety of 
commercially available medicines. Particulars acquired from 
such surveillance may help to accelerate the improvement of 
existing regulations as well as future product development. 
In this current research study we evaluated physical 
parameters of commercially available enalapril maleate 
tablets. 
The oral route of drug administration is the most important 
method of administrating drugs for systemic effects. 
Nevertheless, it is probable that at least 80% of all drugs to 
produce systemic effects are administered by oral route. 
When a new drug is discovered, one of the first question a 
pharmaceutical company asks is whether or not the drug can 
be effectively administered for its intended effects by the 
oral route. Drugs that are administrated orally solid dosage 
forms represent the preferred class of product of the two 
oral solid dosage forms commonly employed, the tablets and 
the capsules, the tablet has a number of advantages1. 
Tablets are divided into two general classes, whether they 
are made by compression or moulding. Compressed and 
moulded tablets are prepared for large scale and small scale 
production respectively2. The choice of tablet manufacturing 
method depends on the dose and the drug's physical 
properties, compressibility and flow of the blend3. Direct 
compression is a process by which tablets are compressed 
directly from mixtures of the drug and excipients, without 
any preliminary treatment. An active pharmaceutical 
ingredient (API), a diluent and a lubricant constitute a 
formula for direct compression4. The emergence of direct 
compression was made plausible after the trade availability 
of directly compressible tablet vehicle that have both fluidity 
and compressibility. Numerous common manufacturing 
issues are ascribed to incorrect powder flow, which include 
non-uniformity in blending, under or over dosage and 
incorrect filling. The simpleness of the direct compression is 
clear that requires a new and critical approach to the 
selection of raw materials, flow properties of powder blends 
and effect of formulation variables on compressibility. 
Additional advantage of direct compression method includes 
wealth and processing without moisture and heat1,5. Despite 
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the fact that it is not well documented in the published 
writings, it would seem crystal clear that fever chemical 
stability problems would be experienced in tablet prepared 
by direct compression as compared to those made by wet 
granulation process. The primary cause of instability in 
tablet is moisture. Moisture plays a significant role not in 
drug stability but in the compressibility characteristics of 
granulation. One other aspect of stability that warrants 
increasing attention is the effect of tablet aging on 
dissolution rates. 
Tablets prepared by granulation show variation in 
dissolution profile which is not commonly observed in 
tablets made by direct compression. The active drug 
particles are liberated after disintegration of tablet prepared 
by direct compression, resulting in comparatively faster 
dissolution6. This is extremely important because the official 
compendium now requires dissolution specification in most 
solid dosage forms. Highly potent drugs with low flow ability 
are not generally prepared by direct compression due to the 
limitation of this method7. 
Enalapril maleate is the maleate salt form of enalapril, a 
derivative combination of L-alanine and L-proline. Enalapril 
maleate is an angiotension converting enzyme inhibitor 
which lowers blood pressure by reducing peripheral 
vascular resistance without comparatively increasing cardiac 
output, heart rate or cardiac contractility. Entire grades of 
essential hypertension particularly in patients with diabetes 
and other chronic kidney disease such as glomerulosclerosis 
can be treated with enalapril. It is also indicated in the 
treatment of heart failure. Hence, an attempt was made for 
preparation of a new formulation of enalapril maleate tablet 
by direct compression with an aim of reducing the lag time 
and providing faster onset of action to reduce the blood 
pressure immediately8. 
MATERIALS AND METHODS 
Direct compression method is used for tablet preparation. 
Various pharmaceutical parameters given in USP were 
studied for enalapril maleate tablet formulation available in 
the local market as well as for new formulation. These 
parameters include appearance, weight variation, hardness, 
friability, content uniformity, disintegration and dissolution 
tests9. 
Materials 
Pure enalapril maleate powder (Sum pharma, Gurgaon, 
Haryana), monobasic sodium phosphate (Merck), 
phosphoric acid (Merck), acetonitrile (Merck). Different 
brand of enalapril maleate were purchased from the market. 
Methods 
Determination of weight variation 
Twenty tablets from both of the brands of enalapril maleate 
were weighed individually with the mentioned analytical 
balance and average weight and the percent deviation was 
determined for each brand10. 
Hardness test 
The hardness of three tablets from each batch was measured 
individually. An anvil driven by electric motor presses the 
tablet at a horizontal position and constant load until the 
tablet breaks. The hardness was measured in terms of 
kg/cm211. 
Friability test 
This test was done for 20 tablets, starting by weighing them 
and then operating the friabilator at 25 rpm for 4 minutes, 
re-weighing the tablets to determine the loss in their 
weight12. 
Disintegration test 
The disintegration time was determined in Phosphate buffer 
(pH 6.8) at 37˚C. Disintegration apparatus with a basket rack 
assembly containing six open-ended tubes and 10-mesh 
screen on the bottom was used. A tablet was placed in each 
tube of the basket and the time for complete disintegration 
of the six tablets was recorded13. 
Drug Content 
Initially weigh the tablet and then powder it. Now the 
powdered tablets are transferred into a 100 ml volumetric 
flask and add 0.1 HCl up to mark. Now filter the solution and 
discard first few ml of filtrate. Take 10 ml of filtrate should 
be taken into a 50 ml volumetric flask and add 0.1 N HCl up 
to the mark and analyzed spectrophotometrically. The 
concentration of the content of the drug (µg/ml) was 
calculated by using the standard calibration curve of the 
respective drug 14. 
Drug content is calculated by using the formula   
Concentration of the in (µg/ml) × 100 × 50 × 1000 
Dissolution studies of Enalapril maleate tablets 
The dissolution test was used to compare between Enalapril 
maleate tablets. The USP paddle method was used for all the 
in vitro dissolution studies. In this method, Phosphate 
buffers (pH 6.8) were used as dissolution media. The rate of 
stirring was 50 ± 2 rpm. The tablets were placed in 900 mL 
of Phosphate buffer (pH 6.8) at 37 ± 0.1°C. At appropriate 
intervals (5, 10, 15, 30, and 60 min), 5 mL of the samples 
were taken and filtered. The dissolution medium was then 
replaced by 5 mL of fresh dissolution fluid to maintain a 
constant volume. The samples were then analyzed by UV-
spectrophotometer (USP 31, 2010). 
RESULTS AND DISCUSSION 
Different brands of Enalapril maleate tablet were evaluated 
that are listed in local index of registered pharmaceutical 
products. All formulation tablets with 5 mg potency were 
selected and then evaluated with same standard procedure. 
Various pharmaceutical parameters namely weight 
variation, hardness test, friability test, disintegration test and 
dissolution test were performed according to USP (2008). 
Results are given in table 1. 
 
Table 1: Evaluation of different quality control parameters of Enalapril maleate tablets 
Sample (Tablet 
Brands) 
Weight variation 
test limit (%) 
Hardness 
(kg/cm²) 
Friability (%) Disintegration 
Time (min/sec) 
Enalapril maleate 
Content (%) 
A 1.91±0.04 7.55±0.05 0.35±0.02 4.46±0.08 98.3±0.41 
B 1.30±0.05 6.45±0.34 0.68±0.35 4.27±0.15 96±0.65 
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Weight variation 
During the study, at first the weight variation is the key to 
controlling crushing strength and friability of tablet was 
assessed. The test stated that both the sample of Enalapril 
maleate coded A and B have passed the weight variation 
uniformity test as specified in the Indian Pharmacopoeia 
(not exceed 5% deviation) (table 1). 
Hardness 
After weight variation hardness is the second most 
important physical feature for assessing tablet. In this 
current research evaluation study, it was found that A and B 
brands of enalapril maleate successfully passed the tablet 
crushing strength or hardness test. Both these commercial 
brands have acceptable crushing strength of range between 
4kg/cm² to 10 kg/cm² (table 1). 
Friability 
In the friability test, both tablet brands showed impressive 
friability values. The friability values for both Enalapril 
maleate brands were ranged from 0.3 to 0.7%. In both 
formulations the percent (%) friability was less than 1% 
which ensures that all the tablets of both brands of 
formulation were mechanically stable (table 1). 
Disintegration 
The disintegration time of both the tablet brands of enalapril 
maleate A and B was found to be satisfactory as compared to 
uncoated USP tablet having disintegration time standards as 
low as 5 minutes (table 1). 
Drug Content 
The drug content of both the brands of enalapril maleate 
showed little differences (table 1). 
Dissolution 
Dissolution was another studied important quantity control 
parameters directly related to the absorption and 
bioavailability of drug. The study revealed that at different 
time intervals drug release rate was better (figure 2) (table 
2). 
 
Figure 1: Calibration curve of Enalapril maleate in 
phosphate buffer 6.8 
 
Table 2: Calibration curve data of Enalapril maleate 
tablets in phosphate buffer 6.8. 
TIME (min) Concentration 
(µg/ml) 
Absorbance 
5 2 0.457±006 
10 4 0.584±007 
15 6 0.737±0.10 
30 8 0.888±0.14 
60 10 0.993±002 
 
 
Figure 2: Drug % release of both the brands (A and B) 
Table 3: Observation of drug % released of both brands 
Time 
(min) 
% drug released (A) % drug released (B) 
0 0 0 
5 50.78±0.65 42.76±0.97 
10 63.54±0.39 64.45±0.67 
15 79.67±0.78 75.76±0.65 
30 84.82±0.69 84.45±0.43 
60 98.21±0.42 95.34±0.66 
 
CONCLUSION 
Enalapril maleate is a well-established and commonly used 
antihypertensive medicine. Therapeutic response of any 
formulation depends on its quality parameters. Study results 
confirm that weight variation and friability test of both 
enalapril maleate tablet brands conform to the specification. 
Variation was found in hardness, disintegration time and 
dissolution profile during the test procedure. Furthermore, it 
confirms that an ideal tablet should have sufficient hardness 
to maintain its mechanical stability but not too much as 
harder tablet can delay disintegration time or alter 
dissolution profile. Finally as quality control parameters are 
related to each other, from initial step to pharmacological 
action of the drug, a high quality tablet should meet all the 
standard quality parameters to exert its desired therapeutic 
response. 
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